Cargando…

PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma

BACKGROUND: The expression of programmed death-ligand 1 (PD-L1) is associated with the response of patients to PD-1/PD-L1 blockade immunotherapy. It has been demonstrated that histone deacetylase (HDAC) inhibitors may alter the expression of PD-L1/PD-L2 and enhance the antitumor immune responses. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zhao, Zhang, Lei, Liu, Jianwei, Yang, Lixue, Xue, Hui, Bai, Shilei, Wang, Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799021/ https://www.ncbi.nlm.nih.gov/pubmed/35116547 http://dx.doi.org/10.21037/tcr-20-3415

Ejemplares similares

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases
por: Liu, Jianwei, et al.
Publicado: (2022)

Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
por: Bai, Shilei, et al.
Publicado: (2022)

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE
por: Bai, Shilei, et al.
Publicado: (2023)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
por: Wang, Haifang, et al.
Publicado: (2020)

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
por: Böger, Christine, et al.
Publicado: (2016)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
por: Yang, Hui, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
por: Wang, Yuqian, et al.
Publicado: (2023)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
por: Chen, Guoming, et al.
Publicado: (2023)

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma
por: Zeng, Hui, et al.
Publicado: (2023)

Comprehensive Analysis of SLC17A9 and Its Prognostic Value in Hepatocellular Carcinoma
por: Kui, Xue-Yan, et al.
Publicado: (2022)

Development and validation of prognostic dynamic nomograms for hepatitis B Virus-related hepatocellular carcinoma with microvascular invasion after curative resection
por: Bai, Shilei, et al.
Publicado: (2023)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model
por: kong, Panpan, et al.
Publicado: (2023)

Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
por: Gong, Xue-Qin, et al.
Publicado: (2023)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma
por: Xue, Feng, et al.
Publicado: (2020)

Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta‐analysis
por: Liu, Jianwei, et al.
Publicado: (2022)

HDAC9 Is Preferentially Expressed in Dedifferentiated Hepatocellular Carcinoma Cells and Is Involved in an Anchorage-Independent Growth
por: Kanki, Keita, et al.
Publicado: (2020)

Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma
por: Zhou, Binghai, et al.
Publicado: (2020)

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
por: Kang, Xindan, et al.
Publicado: (2023)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2020)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
por: Wu, Lei, et al.
Publicado: (2020)

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
por: Yu, Chao, et al.
Publicado: (2023)

PD-L1 in Combination with CD8(+)TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma
por: Zhou, Zihan, et al.
Publicado: (2020)

Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers
por: Kim, Kyung-Ju, et al.
Publicado: (2017)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
por: Liu, Haoran, et al.
Publicado: (2020)

CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling
por: Yang, Lixue, et al.
Publicado: (2020)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
por: Zeng, Zhen, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_18leufii41ti9vc46raci8jg43